Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

SABS

SAB Biotherapeutics (SABS)

SAB Biotherapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SABS
DateTimeSourceHeadlineSymbolCompany
07/31/20234:31PMEdgar (US Regulatory)Form AW - Amendment Withdrawal RequestNASDAQ:SABSSAB Biotherapeutics Inc
07/10/20235:19PMEdgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:SABSSAB Biotherapeutics Inc
07/03/20231:20PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SABSSAB Biotherapeutics Inc
06/21/20238:51AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SABSSAB Biotherapeutics Inc
06/21/20238:30AMGlobeNewswire Inc.SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023NASDAQ:SABSSAB Biotherapeutics Inc
06/14/20238:55AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SABSSAB Biotherapeutics Inc
05/30/20238:30AMGlobeNewswire Inc.SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International ConventionNASDAQ:SABSSAB Biotherapeutics Inc
05/19/20239:30AMEdgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:SABSSAB Biotherapeutics Inc
05/19/20238:30AMGlobeNewswire Inc.SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy InnovationsNASDAQ:SABSSAB Biotherapeutics Inc
05/16/20238:30AMGlobeNewswire Inc.SAB Biotherapeutics Provides Company Update for Q1 2023 Financial ResultsNASDAQ:SABSSAB Biotherapeutics Inc
05/15/20235:06PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SABSSAB Biotherapeutics Inc
05/12/20238:30AMGlobeNewswire Inc.SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal AntibodiesNASDAQ:SABSSAB Biotherapeutics Inc
05/10/20236:06AMEdgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:SABSSAB Biotherapeutics Inc
05/09/20234:14PMEdgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:SABSSAB Biotherapeutics Inc
05/09/20238:30AMGlobeNewswire Inc.SAB Biotherapeutics Announces Progress on U.S. FDA’s Phased Review of Company’s Groundbreaking DiversitAb™ PlatformNASDAQ:SABSSAB Biotherapeutics Inc
05/04/20238:30AMGlobeNewswire Inc.SAB Biotherapeutics Presents Positive Phase 1 and 2a Data for SAB-176 Influenza Immunotherapy at ISIRV-AVG ConferenceNASDAQ:SABSSAB Biotherapeutics Inc
05/03/20235:00PMGlobeNewswire Inc.SAB Biotherapeutics to Present at Sidoti Virtual Investor Conference, May 10-11NASDAQ:SABSSAB Biotherapeutics Inc
04/28/20234:48PMEdgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:SABSSAB Biotherapeutics Inc
04/28/20234:37PMEdgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:SABSSAB Biotherapeutics Inc
04/28/20239:05AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SABSSAB Biotherapeutics Inc
04/26/20238:30AMGlobeNewswire Inc.SAB Biotherapeutics Announces Positive Results from Phase 3 Trial of SAB-185 in Patients with COVID-19 at High-Risk for Severe ComplicationsNASDAQ:SABSSAB Biotherapeutics Inc
04/19/20235:06PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SABSSAB Biotherapeutics Inc
04/18/20238:30AMGlobeNewswire Inc.SAB Biotherapeutics Announces U.S. FDA Grants Breakthrough Therapy Designation to SAB-176 Influenza ImmunotherapyNASDAQ:SABSSAB Biotherapeutics Inc
04/14/20235:00PMEdgar (US Regulatory)Annual Report (10-k)NASDAQ:SABSSAB Biotherapeutics Inc
04/13/20238:30AMGlobeNewswire Inc.SAB Biotherapeutics Granted Fast Track Designation from FDA for SAB-176 Influenza Immunotherapy with High Cross-Reactivity to Multiple Strains of InfluenzaNASDAQ:SABSSAB Biotherapeutics Inc
04/05/20235:02PMEdgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:SABSSAB Biotherapeutics Inc
04/04/20238:00AMGlobeNewswire Inc.SAB Biotherapeutics Announces Appointment of Erick Lucera, CFA to Board of DirectorsNASDAQ:SABSSAB Biotherapeutics Inc
03/31/20235:00PMGlobeNewswire Inc.SAB Biotherapeutics Provides Company Update for Full Year 2022NASDAQ:SABSSAB Biotherapeutics Inc
03/16/20234:29PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SABSSAB Biotherapeutics Inc
03/16/20234:29PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SABSSAB Biotherapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SABS